SARS‐CoV‐2 and inflammatory responses: From mechanisms to the potential therapeutic use of intravenous immunoglobulin. Issue 5 (23rd February 2021)

• Record Type: Journal Article
• Authors: Mascolo, Silvia; Carleo, Maria A.; Contieri, Marcella; Izzo, Sara; Perna, Angelica; De Luca, Antonio; Esposito, Vincenzo
• Other Names: Luo Guangxiang (George) guestEditor.; Ly Hinh guestEditor.; Gao Shou‐Jiang guestEditor.
• Is Part Of: Journal of medical virology. Volume 93:Issue 5(2021)
• Page Start: 2654
• Page End: 2661
• Publication Date: 2021-02-23
• Subjects: immunotherapy -- inflammation -- intravenous immunoglobulin -- SARS‐CoV‐2; Virology -- Periodicals; 616
• DOI: 10.1002/jmv.26651
• Languages: English
• ISSNs: 0146-6615

Abstract

Abstract: A novel coronavirus (SARS‐CoV‐2) is responsible for a severe acute respiratory syndrome called coronavirus disease 2019 (COVID‐19). It is originated in Wuhan, China, in December 2019. Due to its extreme transmissibility with droplets and human contacts, in a few months, it has become a pandemic. Nowadays, no effective therapy is available, and the scientific community is moving to find a therapeutic choice to fight this silent enemy. Studies are ongoing on several therapeutic options, including antiviral agents, immunomodulant drugs, and immunotherapy. Due to viral features, including the ability to start an inflammatory response that seems to be the fulcrum of COVID‐19 pathogenic action, immunotherapy could represent a promising alternative waiting for the vaccine. High‐dose intravenous immunoglobulin (IVIg), already used in other infectious diseases, could represent an effective help. The aim of this narrative review is to reassemble the clinical experiences on the use of IVIg in COVID‐19 and the rationale of its use.